Trial Profile
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Peripheral Spondyloarthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Spondylarthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ABILITY-2
- Sponsors Abbott Laboratories; AbbVie
- 08 Nov 2017 Results of a post-hoc analysis assessing the predictors of long-term minimal disease activity response following adalimumab treatment, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 17 Jun 2017 Results of post-hoc analysis presented at the 18th Annual Congress of the European League Against Rheumatism
- 15 Mar 2017 Results published in The Journal of Rheumatology